Why Aegerion Pharmaceuticals Inc. Shares Were Clobbered

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Aegerion Pharmaceuticals (NASDAQ: AEGR  ) , a biopharmaceutical company focused on developing drugs to treat rare diseases, plunged as much as 31% after reporting disappointing first-quarter results after the closing bell last night.

So what: For the quarter, Aegerion reported $27 million in total sales of Juxtapid, its oral therapy to treat homozygous familial hypercholesterolemia. This figure represents 24% sequential quarterly growth, with 96% of all sales coming from within the U.S. Net loss for the quarter shrank by 50% to $7.3 million or $0.25 per share. But compared to Wall Street's estimates, today was entirely a top-line problem because Wall Street had been expecting Aegerion to record $33.6 million in revenue for the quarter. The company blamed longer turnaround times on price quotes and orders in Brazil, as well as an ongoing investigation into possible violations of anticorruption laws in connection with sales of the drug in Brazil, as a reason ex-U.S. prescriptions dipped 70%.

Given these external pressures Aegerion lowered its full-year sales forecast to $180 million-$200 million from a prior forecast of $190 million-$210 million and forecast reaching positive cash flow status by the second-half of this year.

Now what: Even down nearly 70% from its 52-week high and I still can't say I'm a fan of Aegerion Pharmaceuticals. I still fail to see how it can price its HoFH therapy more than $100,000 over the price of Kynamro, a competing therapy, and expect to thrive. As we're seeing today, drug development is really only half the battle nowadays for biopharmaceutical companies. They also need to be able to properly execute a drug launch and become profitable. At the moment Aegerion is still losing money and it's got a lot of kinks to apparently work through in overseas markets. I know its forward P/E might look appealing, but I'd suggest sticking to the sidelines until we see demonstrable progress from Aegerion in reducing its quarterly losses.

Juxtapid may have world's of potential, but even Aegerion may struggle to keep pace with this top stock over the long run
Give me five minutes and I'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks 1 stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.


Read/Post Comments (2) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On May 07, 2014, at 9:17 PM, MattBerry01 wrote:

    "For the quarter, Aegerion reported $27 million in total sales of Juxtapid, its oral therapy to treat homozygous familial hypercholesterolemia. This figure represents 24% sequential quarterly growth, with 96% of all sales coming from within the U.S."

    From $24.5 million 4thQ'13 to $27 Million 1stQ'14

    = 10% Seq Growth.

    24% was CEO spin ... restricting context to USA slice of the pie. But top line growth = 10%

    Investors also worried about patient population discrepancy of 1,000%, Department of Justice investigation, and lack of closure with FDA warning.

  • Report this Comment On May 07, 2014, at 9:57 PM, TheStockDoctor wrote:

    You say "I still fail to see how it can price its HoFH therapy more than $100,000 over the price of Kynamro, a competing therapy" ... the problem is, Kynamro doesn't work and everybody knows it.

    Seriously, if you were dying from an illness that was 100% fatal and you had 2 choices of medicines. One works 90%+ of the time the other works 10%-15% of the time, would you REALLY try to save the money? Seriously?

    What if it was your child? Would you go cheap then too?

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2948521, ~/Articles/ArticleHandler.aspx, 12/22/2014 5:51:14 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement